Dr Stuart McCrackenClinical Lecturer in Ageing Medicine and Specialist Registrar in Urology
McCracken SRC, Ramsay A, Heer R, Mathers ME, Jenkins BL, Edwards J, Robson CN, Marquez R, Cohen P, Leung HY. Aberrant expression of extracellular signal-regulated kinase 5 in human prostate cancer .
Oncogene 2008, 27 (21), 2978-2988.
Ramsay AK, McCracken SRC, Soofi M, Fleming J, Yu AX, Ahmad I, Morland R, Machesky L, Nixon C, Edwards DR, Nuttall RK, Seywright M, Marquez R, Keller E, Leung HY. ERK5 signalling in prostate cancer promotes an invasive phenotype .
British Journal of Cancer 2011, 104 (4), 664-672.
Dudderidge TJ, McCracken SRC, Loddo M, Fanshawe TR, Kelly JD, Neal DE, Leung HY, Williams GH, Stoeber K. Mitogenic growth signalling, DNA replication licensing, and survival are linked in prostate cancer .
British Journal of Cancer 2007, 96 (9), 1384-1393.
McCracken S, Durkan G, Pickard R, Robson C. Diagnosis and management of prostate cancer in the older man .
Reviews in Clinical Gerontology 2010, 20 (3), 193-204.
Brooke GN, Culley RL, Dart DA, Mann DJ, Gaughan L, McCracken SR, Robson CN, Spencer-Dene B, Gamble SC, Powell SM, Wait R, Waxman J, Walker MM, Bevan CL. FUS/TLS Is a Novel Mediator of Androgen-Dependent Cell-Cycle Progression and Prostate Cancer Growth .
Cancer Research 2011, 71 (3), 914-924.
Mills, I., Gaughan, L., Robson, C. N., Ross, T., McCracken, S. R. C., Kelly, J., Neal, D. E. Huntingtin interacting protein 1 modulates the transcriptional activity of nuclear hormone receptors .
Journal of Cell Biology 2005, 170 (2), 191-200.
Gaughan L, Stockley J, Wang N, McCracken S, Truemann A, Armstrong K, Shaheen F, Watt K, McEwan I, Wang C, Pestell RG, Robson CN. Regulation of the androgen receptor by SET9-mediated methylation .
Nucleic Acids Research 2011, 39 (4), 1266-1279.
Logan IR, Gaughan L, McCracken SRC, Sapountzi V, Leung HY, Robson CN. Human PIRH2 enhances androgen receptor signaling through inhibition of histone deacetylase 1 and is overexpressed in prostate cancer .
Molecular and Cellular Biology 2006, 26 (17), 6502-6510.
Gowardhan B, Douglas DA, Mathers ME, Mckie AB, McCracken SRC, Robson CN, Leung HY. Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer .
British Journal of Cancer 2005, 92 (2), 320-327.
McCracken SRC, Jenkins BL, Heer R, Mathers ME, Robson CN, Leung HY. Expression analysis of the MEK5/ERK5 signalling pathway in human prostate cancer .
BJU International 2005, 95 (s5), 82-83.
Leung HY, Mckie AB, Sahadevan K, McCracken SRC, Maitland H, Olijslagers S. Loss of Sprouty2 Drives an Invasive Phenotype in Prostate Cancer and May Co-operate with HER2/3 in a Subgroup with Aggressive Disease .
In: BJU International: Annual Scientific Meeting of the British Association of Urological Surgeons . 2009, Glasgow, UK: Wiley-Blackwell Publishing Ltd.
Gao ML, Patel R, Ahmad I, Fleming J, Edwards J, McCracken S, Sahadevan K, Seywright M, Norman J, Sansom O, Leung HY. SPRY2 loss enhances ErbB trafficking and PI3K/AKT signalling to drive human and mouse prostate carcinogenesis .
EMBO Molecular Medicine 2012, 4 (8), 776-790.
